a good activator of PKB/Akt but not of mitogen-activated protein (MAP) kinase, failed to induce endogenous BAD phosphorylation, although it did promote survival. In addition, both IL-3 and ...

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that ...